You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 117 No. 8, August 1981 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antinuclear Antibodies and PUVA Photochemotherapy

Raj Kubba, MBBS, MRCP; Willard D. Steck, MD; John D. Clough, MD

Arch Dermatol. 1981;117(8):474-477.


Abstract

• Sequential testing for antinuclear antibody (ANA) in a group of 99 patients receiving long-term methoxsalen (PUVA [methoxsalen plus ultraviolet light]) therapy showed positive tests for ANA in the serum samples of 42 patients. In 22 patients, the ANA was persistent; in seven patients, it was transient; and in the other 13 patients, it developed near the end of the observation period. A causal association between the occurrence of ANA and PUVA therapy is suggested by the incidence of ANA, its conversion from a negative to positive ANA test in 31 of 42 patients, and its statistically significant correlation with the duration of PUVA therapy. The ANA titers were 1:80 or greater in only 12 patients. The staining pattern was homogeneous in 39 patients, speckled in two patients, and nucleolar in one patient. In patients with a positive ANA test, the serologic tests for antibodies to DNA and extractable nuclear antigens were negative. Patients with positive ANA tests were significantly older than patients with negative ANA tests. Symptomatic systemic disease has not developed in any patient with a positive ANA test in this group.

(Arch Dermatol 1981;117:474-477)



Author Affiliations

From the Departments of Dermatology (Drs Kubba and Steck) and Rheumatic and Immunologic Disease (Dr Clough), The Cleveland Clinic Foundation.


Footnotes

Accepted for publication Oct 1, 1980.

Read before the Section of Dermatology of The American College of Physicians, San Francisco, March 25, 1979.

Reprint requests to The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44106 (Dr Steck).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term Risks of Psoralen and UV-A Therapy for Psoriasis
Farber et al.
Arch Dermatol 1983;119:426-431.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.